Recent Updates — BEIGF

BeOne Medicines Ltd. reported third-quarter 2026 total revenues of $1.89 billion, a 34% increase from the prior year, driven by $1.4 billion in BRUKINSA sales and $243 million in TEVIMBRA sales. The company posted diluted GAAP earnings per ADS of $3.28 and raised its full-year 2026 total revenue guidance to $6.9-$7.0 billion, up from the previous range of $6.6-$6.8 billion. Operating income also saw significant growth, with GAAP operating income reaching $419 million for the quarter. BeOne Medicines is a global oncology company that discovers and develops innovative cancer treatments.

BeOne Medicines Ltd. reported second quarter 2026 financial results on August 5, 2026, posting total global revenues of $1.7 billion, a 30% increase from the prior year. BRUKINSA (zanubrutinib) drove growth with $1.2 billion in sales, while diluted GAAP earnings per ADS reached $2.05. The company raised its full-year 2026 total revenue guidance to $6.6–$6.8 billion and updated operating income expectations accordingly. Business highlights include FDA accelerated approval for BEQALZI (sonrotoclax) in relapsed/refractory mantle cell lymphoma, positive Phase 3 MANGROVE study results for BRUKINSA, and the appointment of three new directors to its Board. BeOne Medicines Ltd. is a global oncology company that discovers and develops innovative cancer treatments.